Our Innovation Analysts recently looked into emerging technologies and up-and-coming startups working on solutions for the pharma sector. As there are many startups working on a wide variety of solutions, we want to share our insights with you. This time, we take a look at 5 promising real world evidence startups.
Heat Map: 5 Top Real World Evidence Startups
Using our StartUs Insights Platform, covering 1.116.000+ startups & emerging companies, we looked at innovation in the pharma sector. For this research, we identified 110 relevant solutions and picked 5 to showcase below. These companies were chosen based on a data-driven startup scouting approach, taking into account factors such as location, founding year, and technology among others. Depending on your specific criteria, the top picks might look entirely different.
The Global Startup Heat Map below highlights 5 startups & emerging companies developing real world evidence-based solutions. Moreover, the Heat Map reveals regions that observe a high startup activity and illustrates the geographic distribution of all 110 companies we analyzed for this specific topic.
Pentavere – Unstructured Health Data
Real world evidence (RWE) is clinical evidence derived from a range of interventions that a conventional randomized controlled trial (RCT) does not record and are grouped under real world data (RWD). It mainly comprises unstructured health data from a wide variety of sources. These include patient registries, electronic health records (EHRs), pharmacy and insurance databases, wearables, and patient-powered research networks (PPRN). Pharma companies now collect and analyze RWE to improve their solutions.
Pentavere is a Canadian startup that provides lifesaving insights from unstructured health data. Its proprietary engine, DARWEN, uses artificial intelligence (AI) and natural language processing (NLP) to extract complex information from text data. This includes unstructured documents such as clinical notes, transcription text, lab tests, as well as imaging and pathology reports.
Concerto Health AI – Regulatory Research
Regulatory research in the pharmaceutical industry ensures that the products meet the required standards of safety and efficacy. RWE offers new metrics to measure and improve the methodology and reliability of data in clinical trials. Therefore, including sources of RWE boosts the prospects of pharma companies to receive regulatory approval for clinical trials. The US Food and Drug Administration (FDA) has even issued guidelines on best practices to report pharmacoepidemiologic safety using EHRs.
The US-based startup Concerto Health AI offers integrated real world evidence solutions. It explores research-grade RWD to simulate and compare patient population size and characteristics. This allows companies to quickly find patients who benefit, and are underserved, by current therapeutic approaches. The solution enables robust, high-confidence clinical study designs and external control arms.
AKESO – Real Clinical Practice
Even a clinically-proven drug often shows varied effects in different patients. Other than genetics, these differences usually result from differences in co-morbidities, treatment patterns, or adherence. RWE from electronic health records allows pharma companies to understand these variations and test the efficacy of their drugs in use.
AKESO is a Russian startup that provides RWE reports to pharmaceutical companies. It receives data directly from inventory information approval systems (IIAS) of hospitals and clinics. The solution uses AI and ML to analyze depersonalized EHRs to identify patient profiles and predict key performance indicators (KPI) for preferred therapies. It also enables mathematical modeling of drug efficacy across different patient subgroups.
Embleema – Preclinical Target Discovery
RWE also finds applications in drug target discovery. Real world-based solutions integrate and analyze genomic sequencing data and clinical data from a cohort of patients. It allows pharmaceutical companies to identify biomarker targets of interest. It also offers valuable insights from multi-omics data to guide the development of precise therapies.
The US-based startup Embleema leverages RWE for preclinical target discovery. It integrates omics data, such as genomics, metabolomics, proteomics, and glycomics, from patients with electronic medical records, patient-reported outcomes, and data from connected devices. The solution allows pharma companies to analyze this data to discover pre-clinical targets and speed up approvals for precision medicine drugs.
PatchAi – Clinical Trials
Continued patient management is a challenging task during clinical trials. Analysis of RWE from patients in clinical trials helps researchers understand the factors that contribute to patient drop-outs. Moreover, it also helps accelerate and improve the recruitment process for clinical trials, particularly for rare diseases.
PatchAi is an Italian startup that develops an AI-powered digital health solution for patient engagement and data collection. The Software as a Medical Device (SaMD) platform is a virtual assistant that helps patients play an active role in generating RWE. It focuses on personalized patient experience and engagement to facilitate electronic patient-reported outcomes (ePRO). The solution is configurable for individual study protocols and to optimize clinical trial workflow and timelines.
What About The Other 105 Solutions?
While we believe data is key to creating insights it can be easy to be overwhelmed by it. Our ambition is to create a comprehensive overview and provide actionable innovation intelligence so you can achieve your goals faster. The 5 real world evidence startups showcased above are promising examples out of 110 we analyzed for this article. To identify the most relevant solutions based on your specific criteria, get in touch.